A humanized monoclonal antibody that recognizes the Alpha4beta7 heterodimer, and selectively blocks gut lymphocyte trafficking without interfering with trafficking to the central nervous system.
A monoclonal antibody for the treatment of ulcerative colitis and Crohn’s disease.
it is a gut selective monoclonal antibody against the integrin, alpha four beta seven
A human nice immunoglobulin G1 monoclonal anybody against the alpha4 beta2 integrin that inhibits adhesion of of gut homing lymphocytes T lymphocytes to mucosal addressin cell adhesion molecule 1, selectively down regulates gut inflammation while preserving immune responses.
It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer’s patch adhesion molecule.
An anti-integrin antibody.
It is a selective monoclonal antibody against the integrin alpha4beta7.
The blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.
It blocks the interaction of alpha4 beta7 integrin with the mucosal, addressin cell adhesion molecule1, thereby inhibiting the migration of gut, homing T lymphocytes across the intestinal vascular endothelium, and consequently reduces intestinal inflammation.
It is marketed under the trade name Entyvio.
Pregnancy category US: B
Reactivity with this antibody may show widespread applicability in inflammatory processes of diverse etiologies.
Patients with moderate to severe active ulcerative colitis disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated received either vedolizumab or placebo: 47% of patients who received vedolizumab showed an improvement in symptoms, compared with 26% of patients who received placebo.
The drug maintained the effect up to 52 weeks more effectively than placebo.
In adult patients with moderate to severe active Crohn’s disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated vedolizumab was shown to be more effective than placebo: 15% of patients receiving vedolizumab showed improved symptoms after 6 weeks of treatment, compared with 7% of patients on placebo.
The maintenance of the effect up to 52 weeks was more effective with vedolizumab than with placebo.
Phase 3 clinical trials for Crohn’s Disease and Ulcerative Colitis (GEMINI I, GEMINI II and GEMINI III demonstrated that vedolizumab is an effective and well tolerated drug.